Law360, New York (April 26, 2010, 11:43 AM ET) -- A federal jury has upheld the validity of Pfizer Inc.’s patent covering heartburn treatment Protonix, in a setback for Teva Pharmaceutical Industries Ltd. and other generic-drug makers that had challenged the patent in Pfizer’s infringement case.
The jury in the U.S. District Court for the District of New Jersey on Friday disagreed with allegations by the generic-drug firms that the patent was invalid based on obviousness and double-patenting.
The patent, U.S. Patent Number 4,758,579, covers certain compounds useful for inhibiting gastric acid secretion, including pantoprazole sodium,...
Jury Finds Pfizer's Protonix Patent Valid
To view the full article, take a free trial now.
